The Puraclenz offering is now closed and is no longer accepting investments.


Welcome to the Future of Clean.


Welcome to the Future of Clean.

Old Greenwich, CT
Health Tech
Clean Technology
Goodbye, viruses and mold. Hello to the future of clean. Puraclenz cleans indoor air and exposed surfaces in homes and businesses at the source. Our revolutionary, certified ozone-free PCO technology continuously deactivates dangerous pathogens, including mold spores, viruses, bacteria, fungal allergens, and odors. We’re a revenue-generating, air purification manufacturer and marketing company addressing the $11.6 billion interior air purification market.


Price per Share
Min. Investment
Shares Offered
Offering Type
Offering Max
Days Left


Price per Share
Min. Investment
Shares Offered
Offering Type
Offering Max
Days Left
This offering ended on June 08, 2022 and is no longer accepting investments.

Reasons to Invest

Revolutionary, Low Cost, and Patented Products - Our scientifically proven technology automatically destroys dangerous pathogens mid-air and on surfaces at the source
Massive, Flourishing Market - Puraclenz already has thousands of installations in the $11.6 billion air purification market projected to grow at a 10% CAGR
Experienced and Passionate Team - Previously generated millions in revenue and developed over 20 patent-to-market products

Puraclenz Holdings, Inc. is the parent corporation of Puraclenz LLC, which is a wholly-owned subsidiary. Puraclenz LLC is the operating entity that was formed on June 25, 2020. The Company later formed Puraclenz Holdings, Inc. on December 29, 2021. All investors in this Reg CF offering will become shareholders of Puraclenz Holdings, Inc., which will be the sole member of Puraclenz LLC. The funds raised from this Reg CF offering and received by Puraclenz Holdings, Inc. will flow to Puraclenz LLC on an as-needed basis.


An air purifier redefining the standard of “clean air”

We’re not just another air purifier. Standard air cleaners only trap pathogens that pass through their filter… But us? We clean indoor air and surfaces at the source – destroying viruses, mold and bacteria - what we believe is the premier practice to clean air in today’s world.

Puraclenz provides continuous cleaning coverage with very low energy consumption and a 99% effective rate in eliminating airborne viruses and bacteria. We go beyond the limitations of current ionic purifiers. Our products generate no fumes or harmful chemicals and are certified ozone-free.

With a Puraclenz device, you’re treated like one of NASA’s esteemed astronauts. We use an evolved form of the same technology (photocatalytic oxidation) used to provide clean air to astronauts on the International Space Station. Our products clean the air you breathe using IP-protected innovations.

The last two years of the ongoing global health crisis have created a new need. People are seeking a cost-effective and automatic solution to destroy pathogens mid-air and on surfaces. 

It’s not enough to wear masks and wipe down surfaces anymore. Consumers need a product that raises the bar in technology, design, and price.

We’re currently selling five P-Series SKUs throughout North America, with distribution expanding to Europe, India, Southeast Asia, and Japan. In 2022, Puraclenz plans to introduce four new C-Series SKUs that combine our patented Next-Gen PCO technology with True HEPA. The result? What we believe is the most complete air purifier in the market. 

Model P1500 shown

the problem

Pathogens are too powerful for conventional air purifiers

We live in a world where pathogens dangerously disrupt every aspect of life. COVID-19 did and (continues to do) more damage than just getting people sick. Businesses closed. Graduations were canceled. Celebrations ruined. In the U.S. alone, there have been over 60 million Covid cases and over 829,000 Covid related deaths.

All types of pathogens, like viruses, bacteria, and mold, can cause major worldwide health issues. They are responsible for serious illnesses and infections, and even allergic reactions. Every year, 2.8 million bacterial infections occur in the U.S., and more than 35,000 people die. Up to 11% of people in the U.S. get the influenza flu annually. Even 93% of chronic sinus infections are attributed to mold. Excessive concentrations of bacteria, viruses, and molds can trigger asthma episodes for 15 million Americans.


People spend nearly 90% of their time indoors, and indoor air pollution is a top concern of the EPA. Typical indoor air contains two to five times more pollutants than outdoor air. 

Standard air purifiers clearly aren’t effective enough at destroying these pathogens. HEPA, a standard device, only collects particles that pass through its filter. Then, it uses air changes to clean pathogens in the room. 

These air changes take time. Ten to sixty minutes to be exact. By the time the cleaning is finished, people in the space could have already inhaled the pathogens.

the market

$11.6 billion air purification market with a 10% CAGR

Puraclenz is addressing the fast-growing $11.6 billion air purification market. It’s estimated to accelerate to $22.8 billion over the next six years, with a 10% CAGR. 

Source: Grand View Research

Industry analysts created those market estimates before COVID-19 started. We can only imagine the elevated market potential since the virus took off and developed its growing number of dangerous variants.   

Several companies and technologies compete with us in the Interior Air Quality (IAQ) sector. This sector uses various technologies, including UV light-based systems, hydrogen peroxide, negative ionizers, and more.

Most competitors’ products are considered “passive” devices, which have serious drawbacks:

  • Only treat air that passes through their device

  • Less energy-efficient

  • Regularly require expensive filters changes

  • Do not clean surfaces

There is a large price range for air purification. UV robots can cost $125,000 and small HEPA products cost $99.99. Our tech exceeds both competing capabilities at a price range between $299 and $499.

Our proprietary technology offers a unique market opportunity for powerful, low-cost, and certified safe air. We believe Puraclenz is the lowest cost professional-grade system. 

The company’s patent portfolio protects the advanced PCO design. We have four issued patents and six other pending patents. Plus our mass production process uses trade secrets that allow our purifiers to produce an extraordinarily high density of ions providing an unprecedented competitive advantage in the marketplace.

the solution

Complete air purification through small, inexpensive devices

Puraclenz provides continuous cleaning coverage in large areas with low energy consumption. And it’s easy too. Just plug in the unit, run continuously, and breathe easy knowing any pathogens are being destroyed at the source. 

We believe Puraclenz is the next generation of indoor air purification. Our devices use internal UV light that reflects onto a patented titanium catalyst, generating an extraordinarily high density of positive and negatively charged ions. These ions are the heroes–– they cling to and deactivate the pathogens mid-air and on exposed surfaces.

We now sell three purifier models that clean 750, 1,500, or 3,000 square feet areas. Since Puraclenz generates no fumes or harmful chemicals and is certified ozone-free, it’s safe to use around children and pets. Our lab studies also show, when Puraclenz is used in a room, it overwhelmingly halts the growth of mold. 

Puraclenz develops, manufactures, and markets its proprietary air purification products to businesses and consumers worldwide. In the U.S., we manage all marketing, sales, and customer support activities directly. We currently sell through three distribution channels.

PCO technology has been safely purifying the air and exposed surfaces for over 40 years. We advanced the power and safety of this technology with our patented cell design. Puraclenz’s design generates an extraordinarily high density of pathogen-destroying ions without producing any harmful by-products. Hand-cleaning or HEPA filters don’t cut it. Our design kills the pollutants they miss.

Why invest

Scientifically proven products with over $700,000 revenue and international distribution

Our numbers speak for themselves. Since we launched in May 2021, Puraclenz has already generated over $700,000 in revenue with thousands of installations. Many universities, luxury hotels, schools, fitness centers, grocery stores, and small businesses nationwide are using Puraclenz to clean their air and surfaces.

*Revenue of the company's subsidiary, Puraclenz, LLC.

We currently sell five SKUs through four distribution channels in the U.S., Canada, and Mexico. In the U.S., Puraclenz sells air purification equipment direct to home, business customers from, and in bulk through its team of sales reps and network of distributors. We have master distributor agreements for Canada and Mexico. 

Puraclenz has an aggressive five-year growth plan to address this accelerating market. We hope to see annual revenues of $200 million at the end.

In 2022, Puraclenz plans to introduce four more SKUs and expand worldwide distribution to Europe, Japan, India, Southeast Asia, and the Middle East. 

We project that U.S. distribution will also expand in the next two years. In 2022, Puraclenz hopes to expand distribution to online marketplaces like Amazon,, Rakuten, and Houzz. In 2023 and 2024, we aim that our products will be sold in home retail stores, such as Best Buy, Target, Bed Bath Beyond, Home Depot, Lowes, and more.

Global concerns of viral spread are growing. Every business and household needs better air purification. Our devices are scientifically proven to proactively reduce viruses mid-air and on exposed surfaces.  

We believe Puraclenz’s geographic, application, and technology segmentation offers a large growth potential in the air purification market. Our products are backed by a strong and experienced management team and protected by a global patent portfolio. 

This is your chance to participate in a market opportunity with disruptive technology. We’ve created a low-cost product that efficiently addresses what we feel is the biggest global health crisis in over 100 years. It feels good knowing we’re making a difference.

We’re so proud of our success with Puraclenz in just one year. Your investment will push us closer to our ambitious expansion goals in the years to come. Let’s protect people from pathogens and help them breathe easily. Join us!

In the Press

Yahoo! Finance

Tech Startup Puraclenz™ Launches Powerful Next-Gen Air Purifiers Proven To Proactively Destroy Viruses Mid-Air With Patented "Ozone Free" Ionization Technology


The Puraclenz Air Purifier is Effective Against Bacteria

Associated Press

Tech Startup Puraclenz™ Launches Powerful Next-Gen Air Purifiers Proven To Proactively Destroy Viruses Mid-Air With Patented “Ozone Free” Ionization Technology


Breathe Easy With These Air Purifiers

Offering Summary



Puraclenz Holdings, Inc.

Corporate Address


P.O. Box 733, Old Greenwich, CT 06870

Offering Minimum



Offering Maximum



Minimum Investment Amount

(per investor)




Offering Type



Security Name


Class E Common Stock

Minimum Number of Shares Offered



Maximum Number of Shares Offered



Price per Share



Pre-Money Valuation



*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Investment Incentives and Bonuses*

Early Bird

Friends and Family: Invest within the first 72 hours and receive 15% bonus shares.

Super Early Bird: Invest within the first week and receive 10% bonus shares.

Early Bird Bonus: Invest within the first 2 weeks and receive 5% bonus shares.


Invest $500+: Receive 30% off first purchase (up to $150 retail value)

Invest $1,000+: Receive 1 FREE P750 Purifier ($299 retail value)

Invest $5,000+: Receive 5% bonus shares + Receive 2 FREE Purifiers of your choice (up to $999 retail value)

Invest $10,000+: Receive 7% bonus shares + Receive 3 FREE Purifiers of your choice (up to $1,499 retail value)

Invest $25,000+: Receive 10% bonus shares + Receive 4 FREE Purifiers of your choice (up to $1,999 retail value)

Invest $50,000+: Receive 15% bonus shares + Receive 6 FREE Purifiers of your choice (up to $2,999 retail value)

Invest $100,000+: Receive 20% bonus shares + Receive 8 FREE Purifiers of your choice (up to $4,999 retail value)

*All perks occur when offering is complete.

The 10% StartEngine Owners' Bonus

Puraclenz Holdings, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Class B Non-Voting Common Stock at $8.00 / share, you will receive 10 additional shares of Class B Non-Voting Common Stock, meaning you'll own 110 shares for $800. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Insider Investment Notice

Officers, directors, executives, and existing owners with a controlling stake in the company (or their immediate family members) may make investments in this offering. Any such investments will be included in the raised amount reflected on the campaign page.

Irregular Use of Proceeds

Example - The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments and salary made to one's self, a friend or relative; Any expense labeled "Administration Expenses" that is not strictly for administrative purposes; Any expense labeled "Travel and Entertainment"; Any expense that is for the purposes of inter-company debt or back payments.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$2,761,568.00 USD
$2,049,694.00 USD
Cash And Cash Equivalents
$63,487.00 USD
$268,991.00 USD
Accounts Receivable
$43,078.00 USD
$0.00 USD
Short Term Debt
$1,225,464.00 USD
$2,247,742.00 USD
Long Term Debt
$0.00 USD
$0.00 USD
Revenues And Sales
$595,844.00 USD
$0.00 USD
Costs Of Goods Sold
$294,504.00 USD
$0.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
-$1,313,008.00 USD
-$203,954.00 USD


A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Last Day to Invest: 4 Ways Puraclenz is Changing the Air Purification Industry

4 months ago
The air we breathe is constantly teeming with various microbes, which are harmless. However, certain airborne pathogens can pose a serious threat to human health, particularly for those with weakened immune systems. According to research, up to 93% of chronic sinus infections are attributed to mold, while bacteria and viruses are responsible for triggering asthma episodes in an estimated 15 million Americans. In addition, the flu virus is estimated to cause up to 11% of all respiratory infections in the United States each year.
In today's world, we are constantly bombarded by various pollutants, both inside and outside our homes and workplaces. So, it's essential to keep the air we breathe at the best quality we can. Fortunately, there are several ways to improve the air quality in our homes and workplaces, but many still have flaws and aren't as effective as they should be. Enter Puraclenz. Its patented core technology offers a low-cost air and surface purifier certified to be ozone-free and safe for humans and pets; proven highly effective by multiple independent laboratory tests in combating dangerous viruses, bacteria, and mold including SARS-CoV-2, the virus that causes COVID-19. Puraclenz wants consumers to feel confident that Puraclenz has helped them provide healthier interior air and surfaces in their homes and workplace.
So what sets Puraclenz apart from its competitors? Here are four reasons Puraclenz is the future of clean:

  1. Next-generation tech. Puraclenz uses a unique photocatalytic oxidation method (PCO) to improve air quality indoors at the International Space Station. The Puraclenz device eliminates viruses, bacteria, mold, fungal allergens, and other harmful pathogens found in the air and on exposed surfaces.  
  2. Continuously on, 24/7. Over 40 years of PCO technology have been used for purifying air and surfaces in numerous commercial applications. Our patented cell design has advanced PCO technology to be more powerful and certified safe by independent laboratories. By using ozone-free ions, Puraclenz deactivates indoor pollutants without producing harmful byproducts. 
  3. Puraclenz is scientifically proven. Independently conducted efficacy tests confirm that Puraclenz dynamically destroys mold mid-air and on exposed surfaces, continuously cleaning throughout a typical indoor space 24/7. Puraclenz P3000 units have been proven to be more than 99.7% effective at reducing airborne, methicillin-resistant Staphylococcus epidermidis (MSRE). MSRE is an FDA-recognized substitute for MRSA, strep pneumonia, and strep pyogenes, bacterial agents responsible for many difficult-to-treat and deadly infections.
  4. A passionate, forward-thinking team. In an effective, safe-to-use, and affordable way, Puraclenz is preventing dangerous viruses, mold, and bacteria from infiltrating indoor air and on surfaces, so people worldwide can breathe easier.
Excited about Puraclenz's innovative air purification solution? Learn more and become an early investor today by joining their equity crowdfunding campaign at

Invest Now in Puraclenz

Puraclenz Campaign Ends Tomorrow June 7 at 11:59pm PST

4 months ago

Puraclenz®, maker of professional air and surface purifiers that are low-cost and highly effective against dangerous viruses, bacteria, and mold, including SARS-CoV-2, the virus that causes COVID-19, is ending its Regulation Crowdfunding Campaign tomorrow June 7, 2022 at 11:59pm PST.

In addition to enhancing interior air quality, Puraclenz® comes with no chemicals or other additives, making it a low-cost yet effective solution. Puraclenz's founders developed the technology long before the global pandemic, proven to safely reduce viruses and bacteria that thrive in today's conditions. Based on independent efficacy tests, Puraclenz® P3000 is over 99% effective against the MS2 (the proxy virus of SARS-CoV-2) in the air. In a separate lab test, a Puraclenz® P3000 deactivated 95.4% of dangerous bacteria such as MRSA (Methicillin-Resistant Staphylococcus Aureus).

In the future, interior air purification will look much different than it does today with Puraclenz's patented technology. With its revolutionary natural ionization process, the company redefines how we clean and sanitize spaces, creating high-density ions without generating ozone or using harmful chemicals that can be toxic over time, even in small doses. In both large and small public areas such as restaurants, churches, spas, gyms, homes, waiting rooms, and more, Puraclenz fills spaces with natural ions that proactively kill pathogens in the air around them and on exposed surfaces.

"We're excited to offer a low purchase price and low maintenance cost air purification solution to a much larger audience with the help of our new investor partners," says CEO Chris Dooley.  

Businesses can reduce their dependence on spray disinfectants by using Puraclenz and saving time and money. This innovation significantly speeds up the reopening process, provides workers with a more comfortable and secure office work environment, and enables customers to use indoor services, such as gyms or spas, where they might feel uneasy following two years.

For more information, visit

About Puraclenz: Puraclenz is a company focused on health, wellness, and technology. It has reinvented in-flight air purification using PCO (photocatalytic oxidation) technology previously used to purify the air in the International Space Station. Using their proprietary version of this technology, Puraclenz developed a line of powerful, affordable, and certified ozone-free air purifiers to help businesses reopen quickly. The Puraclenz team is motivated by personal experience and science and founded on their own proprietary technology. Puraclenz's mission is to offer consumers low-priced, high-performance interior air and surface purification products for home and the workplace. In addition to a competitive purchase price and low maintenance cost, they also provide a large area of coverage substantially proven effective in multiple independent laboratory tests against dangerous viruses, bacteria, and mold.

Puraclenz is proven over 99% effective against mold spores on surfaces

4 months ago

New laboratory test results are in! World renown laboratory Eurofins in France conducted a surface test following EN 17272 standards that show a Puraclenz P3000 unit reduced Candida albicans mold by 99.75% inside a large 34.5m3 test chamber. Plates with the live mold spores were placed over 8 feet away from the P3000 device during this test and the Puraclenz unit remotely reduced the pathogen by 99.75% over an 8 hour period. 

Ordinary air purifiers cannot destroy pathogens on surfaces like Puraclenz. Get info on investing in Puraclenz:

Puraclenz proven 99% effective against mold spores on surfaces

Invest now in Puraclenz

Cumulative Revenue Reaches $1 Million

4 months ago

Puraclenz's cumulative booked revenue is now over $1 million including purchase orders received. 

Get info on investing in Puraclenz:

Puraclenz $1 million Cumulative Revenue Reached

Invest Now in Puraclenz

USA Registered Trademark Granted

6 months ago

Puraclenz is pleased to announce that the United States Patent and Trademark Office

 has granted a registered trademark for PURACLENZ

Get info on investing in Puraclenz: 

USA Registered Trademark Granted for PURACLENZ

This important trademark joins the growing intellectual property portfolio owned by Puraclenz summarized below: 

  • Utility Patents protecting Puraclenz’s proprietary cell design that allows our products to generate the highest density of ozone free, photocatalytic oxidation ions in the marketplace: 
    • Issued Patents: USA, Japan, China, Macau (click here for the list) 
    • Pending Patents: India, Canada, Korea, UAE, European Patent Organization.  
  • Pending Design Patents protecting Puraclenz’s P-Series outside shape and proprietary Top Cover design: USA, Hague design application for EU, Switzerland, UK, Canada, Korea and Japan. 
  • Trademarks for PURACLENZ: 
    • USA registered trademark 
    • Mexico registered trademark 
    • Pending Canada trademark 
  • Trade Secrets – Proprietary coating formulation and manufacturing techniques that provide an unprecedented competitive advantage and ensure Puraclenz remains the most technologically advanced PCO air and surface purification design available in the marketplace.  

Invest Now in Puraclenz 

$87k Purchase Order Received from Canadian Distributor

6 months ago

Canada Sales are Scaling Up. Puraclenz’s Canadian master distributor Ogena Solutions has issued a new $87,998 purchase order and also provided a forecast to purchase an additional $280,000 in 2022. Sales in Canada began in January 2022 and Ogena Solutions has made great distribution progress in just several months.

Ogena Solutions. In 2021, Puraclenz entered into an exclusive master distribution agreement with Ogena Solutions to sell our commercial line of products in Canada and to USA Animal Health customers. Ogena Solutions has forged an identity as one of the most respected animal health biosecurity companies in North America and over the last several years has been expanding its knowledge and experience into the human health sector. Following a ‘One Health’ philosophy, Ogena Solutions offers innovative, state-of-the-art products and technologies that meet the highest standards for efficacy, efficiency, and safety, providing best-in-class solutions for government agencies, corporations, and small businesses throughout the continent.

Get info on investing in Puraclenz:

Puraclenz Canada Sales are Scaling Up

Invest Now in Puraclenz

Insider Investment Notice

6 months ago

Puraclenz has an investment update. Insiders made investments in the amount of $10,496 in the Company’s current Reg CF offering. Please refer to the offering materials for further information and refer to the Company’s Risk Factors.

New Supply Chain Agreement Saves 25%

6 months ago

As part of the Company’s major effort to reduce its cost of goods sold and maintain our lowest professional grade pricing model, Puraclenz is moving mass production of its P-series products to Vietnam. 

This will reduce Puraclenz's manufacturing costs by 25% for every P-series product imported into the USA by eliminating the Section 301 tariff and leveraging lower labor costs in Vietnam. Our CEO Chris Dooley has worked with the owners of our new manufacturer for over 20 years. They are a seasoned and trusted supplier to many Fortune 500 companies. The new Manufacturing Agreement was signed on March 25, 2022 and mass production in Vietnam will start before the end of 2022.

 Get info on investing in Puraclenz: 

Puraclenz is the lowest cost professional grade system

Invest Now in Puraclenz


Cumulative Revenue Reaches $885k and 3 New Distributors Signed

6 months ago

Puraclenz continues its strong revenue growth. Puraclenz's cumulative booked revenue is now over $885,000 including purchase orders received. The Company currently sells 5 SKU's through 4 channels of distribution in the USA, Canada and Mexico. In the USA, Puraclenz sells air purification equipment direct to home and business customers from, and in bulk through its team of sales reps and network of distributors.

Puraclenz’s network of authorized distributors is expanding. In the past month, Puraclenz has signed distribution agreements with 3 new distributors in California, North Carolina and Florida who are selling our products to their commercial clients including health care practitioners, municipal government agencies, non-profit organizations, and office space. 


Get info on investing in Puraclenz: 

Puraclenz reaches $885k cumulative revenue

Invest Now in Puraclenz 

We've reached the $100k Milestone

7 months ago

Our entire team is grateful for the tremendous support to all who have invested in our company thus far! There has been incredible momentum behind the campaign and at the moment of this message we have raised over $100k in investments in just over 1 week!

We will be posting updates here at least once per week to keep you apprised of all of the exciting new developments. You can also join the mailing list on our website and stay in touch on Facebook and Instagram.

Puraclenz is proven 95% effective against dangerous bacteria on surfaces

7 months ago

New laboratory test results are in! A laboratory report will be issued showing how Puraclenz technology outperforms ordinary HEPA competitors. 

World renown laboratory Eurofins in France conducted a surface test following EN 17272 standards that show a Puraclenz P3000 unit reduced Staphylococcus aureus bacteria by 95% inside a large 34.5 cubic meter test chamber. Staphylococcus aureus is an FDA recognized surrogate for MRSA, Strep Pnuemoniae and Strep Pyogenes that cause deadly infections. Plates with the live bacteria were placed over 10 feet away from the P3000 device during this test and the Puraclenz unit remotely reduced the pathogen by 95% over an 8 hour period. Ordinary air purifiers cannot destroy pathogens on surfaces like Puraclenz.

A picture containing graphical user interface 
Description automatically generated


Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}